UnitedHealth Stock News

UnitedHealth remains a "Buy" with a $400 price target, reflecting 19% upside and continued market outperformance potential. UNH delivered a Q3 2025 double-beat, posting 12% revenue growth and exceeding both top- and bottom-line estimates. Despite strong results, the stock experienced a post-earnings pullback, likely due to profit-taking after a 44% rally since August.

--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) will release its full year 2025 financial results and provide 2026 financial guidance on Tuesday, January 27, 2026, before the market opens, and will host a teleconference at 8:00 a.m. ET with analysts and investors. This call will be webcast on the Investor Relations page of the company's website (www.unitedhealthgroup.com). The replay will be ...

A discharge petition could force the GOP's hand.

UnitedHealth crashed over 40% YTD as seniors' utilization spiked and MLR neared 90%, but the stock has already rebounded ~25% since my mid‑May Buy. The Q3 showed 12% revenue growth and a 4% EPS beat despite ugly optics; management called trends historically high but consistent, signaling no new MLR shock emerging. UNH is deliberately exiting and repricing uneconomic Medicare Advantage business ...

UnitedHealth Group remains a core dividend growth holding, benefiting from demographic tailwinds and a dominant healthcare ecosystem role. Despite a 41.1% EPS drop in 2025 from elevated medical care ratios, revenue grew 12.2% year-over-year, and long-term growth catalysts remain intact. UNH trades at a forward P/E of 18.9, about 7% below its 10-year average, offering a potential 13% total retur...

The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull market.

UnitedHealth Group stock is trading at an attractive price-to-earnings ratio right now. UnitedHealth's management has a solid plan to improve profit margins.

UnitedHealth's stock has generally underperformed compared to some rivals over the last year, but how does it stand against competitors in the ever-changing healthcare landscape? An in-depth analysis shows strong profitability, consistent revenue growth, and reasonable valuation support.